These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30796310)

  • 1. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.
    Iwahori K; Shintani Y; Funaki S; Yamamoto Y; Matsumoto M; Yoshida T; Morimoto-Okazawa A; Kawashima A; Sato E; Gottschalk S; Okumura M; Kumanogoh A; Wada H
    Sci Rep; 2019 Feb; 9(1):2636. PubMed ID: 30796310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
    Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems pharmacology dissection of
    Huang C; Li Z; Zhu J; Chen X; Hao Y; Yang R; Huang R; Zhou J; Wang Z; Xiao W; Zheng C; Wang Y
    Aging (Albany NY); 2021 Jan; 13(2):2912-2940. PubMed ID: 33460401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic CD8
    Iwahori K
    Adv Exp Med Biol; 2020; 1224():53-62. PubMed ID: 32036604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
    AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Cell Composition in Human Non-small Cell Lung Cancer.
    Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():3101. PubMed ID: 30774636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles.
    Yoon HJ; Kang J; Park H; Sohn I; Lee SH; Lee HY
    PLoS One; 2020; 15(4):e0231227. PubMed ID: 32251447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients.
    Iwahori K; Uenami T; Yano Y; Ueda T; Tone M; Naito Y; Suga Y; Fukushima K; Shiroyama T; Miyake K; Koyama S; Hirata H; Nagatomo I; Kida H; Mori M; Takeda Y; Kumanogoh A; Wada H
    Sci Rep; 2022 Oct; 12(1):17461. PubMed ID: 36261600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment.
    Zhang LN; Xin T; Chen M; Gao P
    IUBMB Life; 2019 Jul; 71(7):986-991. PubMed ID: 31066485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
    de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
    Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.
    Ogawara D; Soda H; Tomono H; Iwasaki K; Hara T; Jinnai S; Funayama T; Okuno D; Taniguchi H; Yoshida M; Harada T; Umemura A; Fukuda Y; Yamaguchi H; Mukae H
    Thorac Cancer; 2018 Oct; 9(10):1305-1311. PubMed ID: 30126069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.